Hepatitis Diagnostic And Treatment Market Size, Share, Opportunities And Trends By Type (Diagnosis, Blood Test, DNA Test, Liver Biopsy, RNA Testing, Liver Ultrasound, Treatment, Drugs, Injectable Alpha Interferons, Liver Transplant), By Disease Type (Hepatitis A, Hepatitis B, Hepatitis C, Others), And By Geography - Forecasts From 2019 To 2024
- Published : Mar 2020
- Report Code : KSI061611513
- Pages : 114
The
hepatitis diagnostic and treatment market was valued at US$XX billion in 2017
and is projected to expand at a CAGR of XX.XX% over the forecast period to
reach US$XX billion by 2023. Hepatitis means inflammation of the liver. There
are several hepatitis viruses that have been categorized as Hepatitis A, B, C,
D, E, and G and among them hepatitis A, B, and C are most common. According to
World Health Organization’s global hepatitis report 2017, hepatitis B and C are
responsible for 96% of all hepatitis mortality. Rising number of hepatitis
infected population, growing consumption of alcohol and drugs and improved
accessibility to hepatitis drug are the major factors that are driving the
market’s growth. With new developments taking place in the treatment of
hepatitis virus, and global players expanding their footprint across
geographies to provide medication for the disease are the factors that will
boost the hepatitis diagnostic and treatment market growth.
By Type
By type,
the hepatitis diagnostic and treatment market has been broadly segmented into
diagnostic and treatment. The hepatitis virus is diagnosed through various
methods such as blood test, DNA test, Liver biopsy, RNA testing and liver
ultrasound and is treated with drugs, injectable alpha interferons and in
adverse cases liver transplant. Hepatitis B and C are considered as chronic
viral hepatitis that are treated via antiviral medicines and injected alpha
interferons.
By Disease Type
By
disease type, the hepatitis diagnostic and treatment market has been segmented
into Hepatitis A, B, C, and others. Others include Hepatitis D, E, and G.
Hepatitis B and C are the most spread diseases around the world.
Hepatitis B is endemic in China and eastern Asia where most people become
infected during childhood.
By Geography
Geographically,
the hepatitis diagnostic and treatment market has been segmented into North
America, Europe, Middle East & Africa, Asia-Pacific and South America
region. North America accounts for the major share in the market owing to the
advanced health infrastructure, accessibility of new drugs and growing
awareness among people about the disease.
Competitive Intelligence
The
hepatitis diagnostic and treatment market is competitive owing to the presence
of major players and regional vendors in the market. The global key
players are Novartis AG, F. Hoffmann-La Roche Ltd, Merk & Co., Inc., Vertex
Pharmaceuticals Incorporated, Bristol-Myers Squibb Company, GlaxoSmithKline
plc, Gilead, Bayer AG, AbbVie Inc., and Janssen Pharmaceuticals, Inc.
Segmentation
The
hepatitis diagnostic and treatment market has been analyzed through following
segments:
By Type
Diagnosis
Blood Test
DNA Test
Liver Biopsy
RNA Testing
Liver Ultrasound
Treatment
Drugs
Injectable alpha Interferons
Liver Transplant
By Disease Type
Hepatitis A
Hepatitis B
Hepatitis C
Others
By Geography
North America
United States
Canada
Mexico
Others
South America
Brazil
Argentina
Others
Europe
Germany
France
Italy
United Kingdom
Others
Middle East and Africa
Israel
Saudi Arabia
UAE
Others
Asia Pacific
Japan
China
India
Australia
South Korea
Others
Target audience
Manufacturers
Suppliers
Distributors
Service Providers
Government Agencies
Research Organizations
Consultants
Key insights offered in “Hepatitis Diagnostic and Treatment Market Report: Trends, Forecast and Competitive Analysis”
What will be the hepatitis
diagnostic and treatment market size from 2018 to 2023?
How are the major drivers
and restraints affecting the hepatitis diagnostic and treatment market growth
and the opportunities which exist for key vendors?
What are the business risks
and threats involved in the hepatitis diagnostic and treatment market?
Which segment of the market
and region will drive or lead the market growth and why?
A comprehensive analysis of
competitive landscape and key market participants’ behavior
Key strategies being
adopted by vendors, with in-depth analysis along with their impact on
competition and market growth.
Analysis on growth
opportunities in different applications and regions of hepatitis diagnostic and
treatments.
Analysis of competitive
intensity of the industry based on Porter’s Five force model
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Force Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness
5. HEPATITIS DIAGNOSTIC AND TREATMENT MARKET BY TYPE
5.1. Diagnosis
5.1.1. Blood Test
5.1.2. DNA Test
5.1.3. Liver Biopsy
5.1.4. RNA Testing
5.1.5. Liver Ultrasound
5.2. Treatment
5.2.1. Drugs
5.2.2. Injectable Alpha Interferons
5.2.3. Liver Transplant
6. HEPATITIS DIAGNOSTIC AND TREATMENT MARKET BY DISEASE TYPE
6.1. Hepatitis A
6.2. Hepatitis B
6.3. Hepatitis C
6.4. Others
7. HEPATITIS DIAGNOSTIC AND TREATMENT MARKET BY GEOGRAPHY
7.1. North America
7.1.1. United States
7.1.2. Canada
7.1.3. Mexico
7.1.4. Others
7.2. South America
7.2.1. Brazil
7.2.2. Argentina
7.2.3. Others
7.3. Europe
7.3.1. Germany
7.3.2. France
7.3.3. Italy
7.3.4. United Kingdom
7.3.5. Others
7.4. Middle East and Africa
7.4.1. Israel
7.4.2. Saudi Arabia
7.4.3. UAE
7.4.4. Others
7.5. Asia Pacific
7.5.1. Japan
7.5.2. China
7.5.3. India
7.5.4. Australia
7.5.5. South Korea
7.5.6. Others
8. COMPETITIVE INTELLIGENCE
8.1. Recent Deals and Investment
8.2. Strategies of Key Players
8.3. Investment Analysis
9. COMPANY PROFILES
9.1. Novartis AG
9.1.1. Company Overview
9.1.2. Financials
9.1.3. Products and Services
9.1.4. Recent Developments
9.2. F. Hoffmann-La Roche Ltd
9.2.1. Company Overview
9.2.2. Financials
9.2.3. Products and Services
9.2.4. Recent Developments
9.3. Merck & Co., Inc
9.3.1. Company Overview
9.3.2. Financials
9.3.3. Products and Services
9.3.4. Recent Developments
9.4. Vertex Pharmaceuticals Incorporated
9.4.1. Company Overview
9.4.2. Financials
9.4.3. Products and Services
9.4.4. Recent Developments
9.5. Bristol-Myers Squibb Company
9.5.1. Company Overview
9.5.2. Financials
9.5.3. Products and Services
9.5.4. Recent Developments
9.6. GlaxoSmithKline plc
9.6.1. Company Overview
9.6.2. Financials
9.6.3. Products and Services
9.6.4. Recent Developments
9.7. Gilead
9.7.1. Company Overview
9.7.2. Financials
9.7.3. Products and Services
9.7.4. Recent Developments
9.8. Bayer AG
9.8.1. Company Overview
9.8.2. Financials
9.8.3. Products and Services
9.8.4. Recent Developments
9.9. AbbVie Inc.
9.9.1. Company Overview
9.9.2. Financials
9.9.3. Products and Services
9.9.4. Recent Developments
9.10. Janssen Pharmaceuticals, Inc
9.10.1. Company Overview
9.10.2. Financials
9.10.3. Products and Services
9.10.4. Recent Developments
LIST OF FIGURES
LIST OF TABLES
Related Reports
Report Name | Published Month | Get Sample PDF |
---|---|---|
Dust Control Systems Market Size & Share: Industry Trends, 2021-2026 | Jul 2021 | |
Pleated Filters Market Size & Share: Industry Report, 2023 - 2028 | Feb 2023 | |
Organoid Technology Market Size & Share: Report, 2022-2027 | Apr 2022 | |
Autoimmune Hepatitis Pipeline Analysis 2018 | Industry Report | Forecasts till 2024 | Mar 2020 |